DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression

Cancer Letters

Volumn 359, Issue 2, 2015, Pages 198-205

  Ning, Xianghong ^a   Shi, Zhendong ^a,b,c   Liu, Xi ^a   Zhang, Anling ^a,b,c   Han, Lei ^a,b,c   Jiang, Kui ^a   Kang, Chunsheng ^a,b,c,d   Zhang, Qingyu ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Binhai Neurological Institute   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d Chinese Glioma Cooperative Group (CGCG)   (China)

Author keywords

DNA methylation; DNMT; EZH2; Histone modifications; MiR 200

Indexed keywords

3 DEAZANEPLANOCIN A; AZACITIDINE; DNA METHYLTRANSFERASE 1; HISTONE H3; HISTONE METHYLTRANSFERASE; LYSINE; MICRORNA; MICRORNA 200A; MICRORNA 200B; MICRORNA 429; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; 3-DEAZANEPLANOCIN; 5 AZA 2' DEOXYCYTIDINE; ADENOSINE; ANTINEOPLASTIC AGENT; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; EZH2 PROTEIN, HUMAN; HISTONE; MIRN200 MICRORNA, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BGC 823 CELL LINE; CANCER GROWTH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG MECHANISM; EPIGENETICS; GASTRIC CANCER CELL LINE; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL LINE; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MGC 803 CELL LINE; MICRORNA 200A GENE; MICRORNA 200B GENE; MICRORNA 429 GENE; MOUSE; MULTIGENE FAMILY; NONHUMAN; PROMOTER REGION; PROTEIN DETERMINATION; RNA INTERFERENCE; STOMACH CARCINOMA; TRANSCRIPTION REGULATION; U87 MG CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DISEASE COURSE; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PHYSIOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE; TUMOR VOLUME;

ADENOSINE; ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; HISTONES; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 2; STOMACH NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923106261     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.005     Document Type: Article

References (43)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Wiklund E.D., Bramsen J.B., Hulf T., Dyrskjot L., Ramanathan R., Hansen T.B., et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer 2011, 128:1327-1334.
3. Davalos V., Moutinho C., Villanueva A., Boque R., Silva P., Carneiro F., et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012, 31:2062-2074.
4. Enkhbaatar Z., Terashima M., Oktyabri D., Tange S., Ishimura A., Yano S., et al. KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. Cell Cycle 2013, 12:2100-2112.
5. Hermann A., Gowher H., Jeltsch A. Biochemistry and biology of mammalian DNA methyltransferases. Cell. Mol. Life Sci 2004, 61:2571-2587.
6. Kanai Y., Ushijima S., Nakanishi Y., Sakamoto M., Hirohashi S. Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers. Cancer Lett 2003, 192:75-82.
7. He M., Fan J., Jiang R., Tang W.X., Wang Z.W. Expression of DNMTs and genomic DNA methylation in gastric signet ring cell carcinoma. Mol. Med. Rep 2013, 8:942-948.
8. Mirza S., Sharma G., Parshad R., Gupta S.D., Pandya P., Ralhan R. Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J. Breast Cancer 2013, 16:23-31.
9. Nakagawa T., Kanai Y., Saito Y., Kitamura T., Kakizoe T., Hirohashi S. Increased DNA methyltransferase 1 protein expression in human transitional cell carcinoma of the bladder. J. Urol 2003, 170:2463-2466.
10. Nakagawa T., Kanai Y., Ushijima S., Kitamura T., Kakizoe T., Hirohashi S. DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis. J. Urol 2005, 173:1767-1771.
11. Peng D.F., Kanai Y., Sawada M., Ushijima S., Hiraoka N., Kosuge T., et al. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci 2005, 96:403-408.
12. Etoh T., Kanai Y., Ushijima S., Nakagawa T., Nakanishi Y., Sasako M., et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am. J. Pathol 2004, 164:689-699.
13. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
14. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
15. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11606-11611.
16. Cai M.Y., Hou J.H., Rao H.L., Luo R.Z., Li M., Pei X.Q., et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol. Med 2011, 17:12-20.
17. McGarvey K.M., Fahrner J.A., Greene E., Martens J., Jenuwein T., Baylin S.B. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006, 66:3541-3549.
18. Qian X., Ren Y., Shi Z., Long L., Pu P., Sheng J., et al. Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. Mol. Pharm 2012, 9:2636-2645.
19. Smits M., Nilsson J., Mir S.E., van der Stoop P.M., Hulleman E., Niers J.M., et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 2010, 1:710-720.
20. Karam J.A., Fan J., Stanfield J., Richer E., Benaim E.A., Frenkel E., et al. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int. J. Cancer 2007, 120:1795-1802.
21. Shi Z., Zhang J., Qian X., Han L., Zhang K., Chen L., et al. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res 2013, 73:5519-5531.
22. Cong N., Du P., Zhang A., Shen F., Su J., Pu P., et al. Downregulated microRNA-200a promotes EMT and tumor growth through the Wnt/β-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma. Oncol. Rep 2013, 29:1579-1587.
23. Zhou J., Bi C., Cheong L.L., Mahara S., Liu S.C., Tay K.G., et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 2011, 118:2830-2839.
24. Neves R., Scheel C., Weinhold S., Honisch E., Iwaniuk K.M., Trompeter H.I., et al. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res. Notes 2010, 3:219.
25. Inoue A., Kawakami C., Takitani K., Tamai H. Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. J. Pediatr. Hematol. Oncol 2014, 36:e322-e324.
26. Nishihori T., Perkins J., Mishra A., Komrokji R., Kim J., Kharfan-Dabaja M.A., et al. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biol. Blood Marrow Transplant 2014, 20:776-780.
27. Liu W.B., Jiang X., Han F., Li Y.H., Chen H.Q., Liu Y., et al. LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer. Cell Death Dis 2013, 4:e882.
28. Xiao X., Zhao W., Tian F., Zhou X., Zhang J., Huang T., et al. Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma. Tumour Biol 2014, 35:3755-3763.
29. Yan H., Yu N., Tong J. Effects of 5-Aza-2'-deoxycytidine on the methylation state and function of the WWOX gene in the HO-8910 ovarian cancer cell line. Oncol. Lett 2013, 6:845-849.
30. Tan J., Yang X., Zhuang L., Jiang X., Chen W., Lee P.L., et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007, 21:1050-1063.
31. Crea F., Hurt E.M., Mathews L.A., Cabarcas S.M., Sun L., Marquez V.E., et al. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol. Cancer 2011, 10:40.
32. Manavalan T.T., Teng Y., Litchfield L.M., Muluhngwi P., Al-Rayyan N., Klinge C.M. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS ONE 2013, 8:e62334.
33. Vrba L., Jensen T.J., Garbe J.C., Heimark R.L., Cress A.E., Dickinson S., et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 2010, 5:e8697.
34. Vella S., Gnani D., Crudele A., Ceccarelli S., De Stefanis C., Gaspari S., et al. EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD. Int. J. Mol. Sci 2013, 14:24154-24168.
35. Diaz T., Tejero R., Moreno I., Ferrer G., Cordeiro A., Artells R., et al. Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J. Surg. Oncol 2014, 109:676-683.
36. Kurashige J., Kamohara H., Watanabe M., Hiyoshi Y., Iwatsuki M., Tanaka Y., et al. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann. Surg. Oncol 2012, 19(Suppl. 3):S656-S664.
37. Howe E.N., Cochrane D.R., Richer J.K. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 2011, 13:R45.
38. Men D., Liang Y., Chen L. Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients. Cancer Epidemiol 2014, 38:152-156.
39. Paterson E.L., Kazenwadel J., Bert A.G., Khew-Goodall Y., Ruszkiewicz A., Goodall G.J. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 2013, 15:180-191.
40. Soubani O., Ali A.S., Logna F., Ali S., Philip P.A., Sarkar F.H. Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis 2012, 33:1563-1571.
41. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
42. Wu X., Gong Y., Yue J., Qiang B., Yuan J., Peng X. Cooperation between EZH2, NSPc1-mediated histone H2A ubiquitination and Dnmt1 in HOX gene silencing. Nucleic Acids Res 2008, 36:3590-3599.
43. So A.Y., Jung J.W., Lee S., Kim H.S., Kang K.S. DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs. PLoS ONE 2011, 6:e19503.